WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 201795
Description: LY294002 is a morpholine derivative of quercetin. It is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks). Two of these are the proto-oncogene serine/threonine-protein kinase (PIM1) and the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform. With an IC50 of 1.4 uM it is somewhat less potent than wortmannin, another well-known PI3 kinase inhibitor However, LY294002 is a reversible inhibitor of PI3K whereas wortmannin acts irreversibly. Application of LY294002 causes a substantial acceleration of MEPP frequency (150 μM) at the frog neuromuscular junction through a mechanism that is independent of intraterminal calcium. LY294002 causes the release of MEPPs through a perturbation of synaptotagmin function.
MedKoo Cat#: 201795
Chemical Formula: C19H17NO3
Exact Mass: 307.12084
Molecular Weight: 307.34
Elemental Analysis: C, 74.25; H, 5.58; N, 4.56; O, 15.62
LY294002, purity > 99%, is in stock. The same day shipping out after order is received.
Synonym: LY294002; LY-294002; LY 294002
IUPAC/Chemical Name: 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
InChi Key: CZQHHVNHHHRRDU-UHFFFAOYSA-N
InChi Code: InChI=1S/C19H17NO3/c21-17-13-18(20-9-11-22-12-10-20)23-19-15(7-4-8-16(17)19)14-5-2-1-3-6-14/h1-8,13H,9-12H2
SMILES Code: O=C1C=C(N2CCOCC2)OC3=C(C4=CC=CC=C4)C=CC=C13
The following data is based on the product molecular weight 307.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Welling A, Hofmann F, Wegener JW. Inhibition of L-type Cav1.2 Ca2+ channels by 2,(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) and 2-[1-(3-dimethyl-aminopropyl)-5-methoxyindol-3-yl]-3-(1H-indol-3-yl) maleimide (Go6983). Mol Pharmacol. 2005 Feb;67(2):541-4. Epub 2004 Nov 10. PubMed PMID: 15537868.
2: Guo M, Joiakim A, Reiners JJ Jr. Suppression of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated aryl hydrocarbon receptor transformation and CYP1A1 induction by the phosphatidylinositol 3-kinase inhibitor 2-(4-morpholinyl)-8-phenyl-4H-1- benzopyran-4-one (LY294002). Biochem Pharmacol. 2000 Sep 1;60(5):635-42. PubMed PMID: 10927021.
3: Jung YD, Kim MS, Lee KS, Kang IC, Nah AS, Song DU, Yang SY, Kim JK, Ahn BW. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) inhibits nitric oxide production in cultured murine astrocytes. Pharmacol Res. 1999 Nov;40(5):423-7. PubMed PMID: 10527657.
4: Chasserot-Golaz S, Hubert P, ThiersÃ© D, Dirrig S, Vlahos CJ, Aunis D, Bader MF. Possible involvement of phosphatidylinositol 3-kinase in regulated exocytosis: studies in chromaffin cells with inhibitor LY294002. J Neurochem. 1998 Jun;70(6):2347-56. PubMed PMID: 9603199.
5: Rousse S, Montarras D, Pinset C, Dubois C. Up-regulation of insulin-like growth factor binding protein-5 is independent of muscle cell differentiation, sensitive to rapamycin, but insensitive to wortmannin and LY294002. Endocrinology. 1998 Apr;139(4):1487-93. PubMed PMID: 9528925.
6: Nakamura M, Nakashima S, Katagiri Y, Nozawa Y. Effect of wortmannin and 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) on N-formyl-methionyl-leucyl-phenylalanine-induced phospholipase D activation in differentiated HL60 cells: possible involvement of phosphatidylinositol 3-kinase in phospholipase D activation. Biochem Pharmacol. 1997 Jun 15;53(12):1929-36. PubMed PMID: 9256168.
7: Yano H, Agatsuma T, Nakanishi S, Saitoh Y, Fukui Y, Nonomura Y, Matsuda Y. Biochemical and pharmacological studies with KT7692 and LY294002 on the role of phosphatidylinositol 3-kinase in Fc epsilon RI-mediated signal transduction. Biochem J. 1995 Nov 15;312 ( Pt 1):145-50. PubMed PMID: 7492304; PubMed Central PMCID: PMC1136237.
8: Smith LK, Vlahos CJ, Reddy KK, Falck JR, Garner CW. Wortmannin and LY294002 inhibit the insulin-induced down-regulation of IRS-1 in 3T3-L1 adipocytes. Mol Cell Endocrinol. 1995 Aug 30;113(1):73-81. PubMed PMID: 8674815.
9: Yamamoto-Honda R, Tobe K, Kaburagi Y, Ueki K, Asai S, Yachi M, Shirouzu M, Yodoi J, Akanuma Y, Yokoyama S, et al. Upstream mechanisms of glycogen synthase activation by insulin and insulin-like growth factor-I. Glycogen synthase activation is antagonized by wortmannin or LY294002 but not by rapamycin or by inhibiting p21ras. J Biol Chem. 1995 Feb 10;270(6):2729-34. PubMed PMID: 7852343.
10: Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994 Feb 18;269(7):5241-8. PubMed PMID: 8106507.
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), two of which are the proto-oncogene serine/threonine-protein kinase (PIM1) and the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform. With an IC50 of 1.4uM it is somewhat less potent than wortmannin, another well-known PI3 kinase inhibitor. However, LY294002 is a reversible inhibitor of PI3K whereas wortmannin acts irreversibly.
Research data showed that LY294002 inhibited the phosphorylating of Akt (S473), cell proliferation, and induced apoptosis in CNE-2Z cells. Moreover, the apoptosis-induced LY294002 was directly regulated by caspase-9 activation pathway, which suggested that PI3K inhibitor, LY294002, induced apoptosis by caspase-9 activation pathway and might be as a potentially useful target for therapeutic intervention in nasopharyngeal carcinoma patients. Fro detail see: http://www.ncbi.nlm.nih.gov/pubmed/20412566.